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Abstract 28 
Background 29 
The spectrum of inflammatory marker response in DRESS syndrome has not been 30 
systematically characterized.  31 
Methods 32 
An epidemiological biomarker study of C-reactive protein (CRP) and procalcitonin 33 
(PCT) values in patients with DRESS syndrome reported to two regional 34 
pharmacovigilance centers (RPVC) in Switzerland or published in the medical 35 
literature 2008-2016 was performed. 36 
Results 37 
Ninety-four DRESS cases were studied. All cases showed a CRP value above 10 38 
mg/L (upper limit of normal) and mean CRP value was 109.2 ± 79.4mg/L. CRP 39 
values were significantly higher in 22 cases where an additional cause of 40 
inflammation beside DRESS could not be excluded (mean=162.1 vs. 92.9mg/L, 41 
p=0.003). Receiver Operator Characteristic curve analysis showed moderate 42 
performance with a CRP cut-off of 99.4mg/L (AUC 0.717) to distinguish between 43 
patients with and without a possible additional cause of inflammation. The mean and 44 
median PCT values were 2.44±5.94ng/ml and 0.69ng/ml, respectively (n=25 45 
patients). Patients in whom an additional cause of inflammation beside DRESS 46 
syndrome could not be excluded, showed a median PCT of 1.37ng/ml (n=9) 47 
compared to 0.67ng/ml (n=16) among patients with DRESS-syndrome alone.  PCT 48 
values were above the normal cut-off of 0.1ng/ml suggestive of bacterial infection in 49 
all but one case. Furthermore, there was a correlation between PCT values and 50 
hepatic enzyme measurements.   51 
Conclusions 52 
Evaluating CRP- and PCT-values might be of use in helping physicians to distinguish 53 
between cases of DRESS syndrome with and without concurrent infection or other 54 
causes of inflammation. Further prospective investigation is required to define the 55 
use of these inflammatory markers in the management of DRESS. 56 
 57 
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Introduction 59 
Inflammation occurs in the delayed-type adverse drug reaction called DRESS (drug 60 
reaction with eosinophilia and systemic symptoms) syndrome. Typical features of 61 
DRESS include fever, lymphadenopathy, a skin eruption and involvement of an 62 
organ, most commonly the liver [1]. The diagnostic criteria for DRESS are defined by 63 
the RegiSCAR Score, derived from data collected by the European Registry of 64 
Severe Cutaneous Adverse Reactions (SCAR) to drugs published by Kardaun and 65 
colleagues [1]. The Score is based on both clinical and laboratory features, the latter 66 
include haematological abnormalities and markers of organ involvement. A 67 
particularity of DRESS is a late onset of symptoms, namely 2-8 weeks after starting 68 
the culprit drug. Symptoms persist for at least two weeks or more after onset, despite 69 
removal of the culprit drug. Early and accurate diagnosis of DRESS remains 70 
challenging since DRESS may be confused with other causes of systemic 71 
inflammation including autoimmune diseases and viral, bacterial or parasitic 72 
infections. The interpretation of laboratory markers of inflammation is particularly 73 
challenging in cases where for example an antibiotic used to treat an infection may 74 
have caused DRESS. Approximately 23% of DRESS cases in the RegiSCAR study 75 
were caused by antibiotics [1]. In other cases, physicians may be prompted to initiate 76 
antibiotics due to elevated inflammatory markers, when these might not be indicated.  77 
Cases of suspected DRESS syndrome therefore often pose diagnostic challenges 78 
and therapeutic dilemmas to the treating physicians – particularly with regard to 79 
commencing or continuing anti-infective treatment.  Moreover, the clinical course of 80 
DRESS is worsened if the diagnosis is delayed and the culprit drug not discontinued.   81 
Laboratory markers of inflammation include elevated C-reactive protein (CRP) and 82 
leucocyte counts. CRP is an acute phase protein, which increases up to 1000 fold in 83 
inflammation. CRP is produced by the liver in response to increased IL-6 and has 84 
pro-inflammatory effects in mediating both the humoral and the cellular effector cell 85 
pathway of the innate immune system [2]. Normal laboratory values in the population 86 
are up to 10 mg/L. Values above this are considered to be associated with 87 
inflammation. A study of 545 patients found that among 53 patients with CRP values 88 
>100 mg/L, 83% had bacterial infections [3]. Another study of 130 patients with CRP 89 
level >500 mg/L found bacterial infection was the underlying cause in 88% [4]. 90 
However, non-bacterial inflammation may cause equally high elevation of CRP. A 91 
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study of 24 patients with DRESS syndrome showed a mean CRP value of 131 mg/L 92 
(14-467 mg/L) and in 8 patients CRP values >150 mg/L [5]. The study also showed 93 
leucocyte count elevation with a mean value of 18.5 G/L in DRESS patients (normal 94 
range 4-10 G/L). 95 
A more specific marker of bacterial infection is procalcitonin (PCT). Its value 96 
correlates with the severity of the infection. The normal range is < 0.1 ng/mL [6]. Like 97 
CRP, it may increase up to 1000 fold, and is part of a tissue-based host defense 98 
mechanism. A cutoff value of <1 ng/mL is proposed to distinguish bacterial infections 99 
from a viral infection [7] or autoimmune inflammatory condition [8] for example. Meta-100 
analyses have shown that PCT has higher accuracy than CRP in distinguishing 101 
bacterial from viral infection and other inflammatory conditions such as exacerbation 102 
of an underlying autoimmune disease or drug fever [9-11]. However, PCT may be 103 
elevated in the absence of a bacterial infection for example after tissue damage due 104 
to severe mechanical or surgical trauma, chemical pneumonitis, pancreatitis, burns or 105 
heatstroke. Whether PCT is elevated in DRESS patients is not currently well 106 
described due to a paucity of data. Only a few literature cases and studies report 107 
PCT values [12-15].  108 
Because the extent of CRP and PCT elevation in patients with DRESS syndrome is 109 
currently not accurately known, we conducted a study looking at these parameters in 110 
DRESS cases reported to the pharmacovigilance centers in north-western and 111 
southern Switzerland and cases reported in the medical literature. 112 
 113 
 114 
Material and Methods 115 
Selection of cases 116 
A retrospective descriptive analysis was performed. The data were obtained from 117 
individual case safety reports (ICSRs) in the databases of the Regional 118 
Pharmacovigilance Centers (RPVCs) in north-western and southern Switzerland. 119 
Both RPVCs report to the Swiss Drug Authority Swissmedic that is part of the drug 120 
monitoring system coordinated by the World Health Organization (WHO). All data 121 
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from the RPVCs are reported in a completely anonymised fashion so no approval 122 
from the ethics committee was needed for this study according to Swiss law. 123 
We searched the database of the two regional centers for cases reported between 124 
2008-2016 that contained either the adverse drug reaction term “DRESS” or two 125 
characteristic DRESS features occurring as joined terms in the ICSR title: 126 
“hypersensitivity reaction”, “hypereosinophilia”, “rash”, “liver enzyme elevation”, 127 
“interstitial pneumonitis”, “interstitial nephritis” and “myocarditis”. No ICSRs were 128 
published in the medical literature and all were scrutinized for double-reporting. In 129 
order to compare the data from the DRESS cases of the RPVCs with published case 130 
reports, we searched PubMed-MEDLINE for “DRESS”, “drug reaction with 131 
eosinophilia and systemic symptoms” or “drug-induced hypersensitivity syndrome” 132 
and “C-reactive protein” or “Procalcitonin” with and without the use of Medical Subject 133 
Headings (MeSH) terms. Case reports were limited to the years 2009 – 2016 and to 134 
those published in English, French or German. No conference abstracts were 135 
included. Cases for which at least one CRP or PCT value were available were 136 
included.  137 
We evaluated each RPVC DRESS case by applying the RegiSCAR scoring system 138 
[1]. Cases were classified as either a “definite case” (more or 6 points), a “probable 139 
case” (4-5 points), a “possible case” (2-3 points) or “no case” (0-1 point). Cases with 140 
scores below two points were excluded from the analysis (Figure 1). 141 
The RegiSCAR scoring system includes clinical and haematological characteristics, 142 
namely fever >38.5°, lymphadenopathy, eosinophilia >700/µl, presence of atypical 143 
lymphocytes, rash on more than 50% of the body surface, exanthema suggestive of 144 
DRESS including maculopapular exanthema, palpable purpura, facial oedema or 145 
desquamation, skin biopsy compatible with DRESS, the involvement of an organ 146 
(liver, kidney, lung, heart), time to resolution more than 15 days and the exclusion of 147 
more than three differential diagnoses among the following: Infection with Hepatitis A, 148 
B or C, mycoplasma- or chlamydia pneumonia and other positive serology, polymer 149 
chain reaction (PCR), blood cultures or antinuclear antibodies (ANA) results [1].  150 
Literature cases were evaluated either according to their published scores if available 151 
(RegiSCAR score or Japanese consensus group for drug-induced hypersensitivity 152 
syndrome [16]) or according to the RegiSCAR score determined using the reported 153 
clinical details. Missing values were awarded the same number of points as values 154 
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not fulfilling the diagnostic criteria in accordance with the instructions for completing 155 
the RegiSCAR DRESS validation score [1]. Therefore the presence of missing data 156 
points could not lead to over-rating of cases and is likely to have caused under-rating 157 
in some instances.   158 
For each case, we determined if another underlying condition such as infection, 159 
autoimmune disease or malignancy (all known to be associated with raised 160 
inflammatory markers [17-19]) could have also caused CRP and PCT elevation. 161 
Cases where DRESS was the only cause for inflammation were assigned to group A 162 
and the remaining cases to group B for ease of comparison (Figure 1). 163 
Data collection 164 
Demographic features (sex and age), laboratory values (peak of available values for 165 
CRP, PCT, leucocyte and eosinophil counts), clinical features (presence of fever, 166 
lymphadenopathy, organ involvement, skin manifestation, outcome) and suspected 167 
drugs along with their corresponding indications were extracted from the ICSRs and 168 
the literature case reports and listed in an electronic spreadsheet (MS Excel 2010). 169 
Furthermore, the association between the suspected drug and DRESS as given in 170 
the RPVC reports was recorded.  In the ICSRs, the suspected drugs were assessed 171 
by the pharmacovigilance experts at the RPVCs as having a “certain”, “probable”, 172 
“possible” or “unlikely” causal relationship with the development of DRESS according 173 
to the WHO-UMC system for causality assessment [20]. All cases in which the use of 174 
more than one possible culprit drug or another possible underlying disease were 175 
present were classified as “possible” and cases unlikely to be caused by another 176 
drug or condition were classified as “probable”. A “certain” drug causality is defined 177 
for a drug showing a positive rechallenge (a repeated DRESS event occurring after 178 
re-administration of the culprit drug). Drugs taken over a period of > 3 months were 179 
labelled as “unlikely” for causing DRESS, analogous to the RegiSCAR study [1]. 180 
 181 
Statistical analysis 182 
Statistical analysis was descriptive and was performed using Microsoft Office Excel 183 
2010. Mean and standard deviation, median and quartile values were calculated as 184 
appropriate. P-values were calculated by application of two-tailed Students t-test. 185 
Non-normally distributed data were log-transformed prior to performing t-tests. 186 
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Receiver operator characteristic (ROC) analysis was performed to determine optimal 187 
cut-off values for CRP and PCT in distinguishing cases without and with an additional 188 
cause of inflammation (groups A and B respectively). These analyses were 189 
performed using VassarStats [21]. Pearson correlation coefficients ( r ) were 190 
determined to assess associations between PCT values and other laboratory 191 
markers, namely liver function tests, creatinine and eosinophilia.   192 
 193 
 194 
Results 195 
Case characteristics 196 
A total of 103 potential DRESS cases were identified. Of these, 94 were included: 39 197 
cases from Swiss RPVCs (24 from north-western and 15 from southern Switzerland) 198 
and 55 cases from the literature search [13, 14, 22-69] (Figure 1). Details of the 55 199 
literature cases are given in the supplementary table. A comparison of demographic 200 
and clinical features is shown in Table 1. Average age was higher among the RPVC 201 
cases than in the literature cases with the latter showing a wider age range as seven 202 
paediatric DRESS cases (none of them neonates) were included. In both groups, 203 
female sex was predominant. Classification of cases by the RegiSCAR Score 204 
showed a higher percentage of “definite cases” among the literature cases. Two 205 
cases in each group had a fatal outcome. In a third of all cases, skin histology 206 
showing perivascular lymphocytic infiltration or epidermal spongiosis was present. 207 
Additionally, in a third of cases more than three differential diagnoses with similar 208 
clinical skin and organ involvement were tested for and excluded.  209 
In all cases together, 57 different culprit drugs were implicated (Table 2).  A third of 210 
the culprit drugs were antibacterial drugs, followed by antiepileptic drugs (23% of all 211 
cases), sulfonamides (15%) and allopurinol (11%). Among the RPVC cases, only one 212 
case showed positive rechallenge and was classified as “certain” and 17 cases 213 
showed “probable” causality.  214 
 215 
 216 
 217 
9 
 
CRP, PCT, leucocyte and eosinophil values 218 
Values of CRP, PCT and eosinophil count with corresponding leucocyte counts are 219 
shown in Table 3. The distribution of CRP and PCT values is illustrated in Figure 2. 220 
CRP was measured in 99% of cases and PCT values were measured in 27% of 221 
cases. Leucocyte and eosinophil counts were measured in more than 80% of cases.  222 
Cases where an additional cause for inflammation could not be excluded 223 
We evaluated whether an additional underlying condition could have been 224 
responsible for the clinical and laboratory inflammation features. Twenty-five of 39 225 
RPVC cases had DRESS syndrome as the only cause of inflammation (group A) 226 
while the remaining 14 cases were evaluated as having a possible additional cause 227 
for the elevation in inflammatory markers (group B). In 12 of these 14 cases an active 228 
bacterial infection occurred simultaneously with the DRESS syndrome. These were 229 
pneumonia (2 cases), cerebral abscess (2 cases), other abscess (2 cases), septic 230 
arthritis (2 cases), other bacterial infections (2 cases) and sepsis (2 cases). Two 231 
DRESS cases occurred in patients with haematological malignancies. In the literature 232 
cases, only nine of 55 cases question another possible additional reason for an 233 
inflammatory response. These cases included pneumonia (1 case), septic arthritis (2 234 
cases), osteomyelitis (3 cases), sepsis (2 cases) and a first episode of Crohn’s 235 
disease (1 case). In both groups with other possible causes for inflammation, 236 
“definite”, “probable” and “possible” DRESS cases were evenly distributed.  237 
Table 4 shows the comparison between all mean and median values of CRP, PCT, 238 
leucocyte and eosinophil count of cases with inflammation just related to DRESS 239 
(group A) and cases, where additional causes for inflammation were possible (group 240 
B). Mean CRP values are significantly higher in group B compared to group A. ROC 241 
analysis gave an area under the curve of 0.717 for a cut-off CRP value of 99.4 mg/L 242 
to distinguish between patients without and with an additional cause of inflammation. 243 
Median of PCT values were 0.67 ng/mL and 1.37 ng/mL in groups A and B, 244 
respectively. A single outlier in group A (30.17 ng/mL) was included in all 245 
calculations, but is not displayed (Figure 3) in order to optimize graphical display. 246 
However, the difference was not significant (Table 4). ROC analysis of PCT gave an 247 
area under the curve of 0.677 for a cut-off PCT value of 2.74 ng/mL. Leucocyte 248 
counts showed similar median values in both groups, eosinophil count however 249 
showed slightly higher median values in group B.  250 
10 
 
PCT values were studied in further detail with regard to their association with other 251 
laboratory markers. Moderate correlations were found between PCT and alanine 252 
aminotransferase and aspartate aminotransferase and a strong correlation was found 253 
between PCT and gamma glutamyl transpeptidase (Table 5).   254 
 255 
Discussion 256 
In this observational study of 39 DRESS cases reported to the RPVC in north-257 
western and southern Switzerland and 55 cases reported in the literature we found 258 
that CRP, PCT, leucocyte and eosinophil values are elevated, in some cases to 259 
levels seen in acute, serious infections. Furthermore, we observed that CRP and 260 
PCT values were higher in cases with a possible additional reason for inflammation.  261 
 262 
 263 
Case characteristics  264 
The demographic and clinical features of the cases reported here are similar to those 265 
of a recently published series with 45 cases [70] and a retrospective review of 172 266 
published cases [71], in which 72% of cases were classified as definite or probable 267 
DRESS cases according to the RegiSCAR score (comparable to the 80% in the 268 
present study).  269 
The most frequently reported drugs in this study were sulfasalazine, carbamazepine 270 
and allopurinol. These were also the most frequently reported drugs in the literature 271 
review of 2011, followed by other antiepileptic drugs, with antibiotics only being 272 
related to a minority of cases [71]. However, in our analysis of RPVC and literature 273 
cases, one third of all suspected drugs were antibiotics and 90% of cases where an 274 
additional cause for inflammation could not be excluded were related to antibiotics. 275 
Eight of these were under polymedication, three patients even received both, 276 
antibiotic and antiepileptic drugs for intracranial abscess or meningitis complicated by 277 
epilepsy. Such clinical situations are additionally challenging for two reasons. Firstly, 278 
it is difficult to determine if inflammation markers are elevated due to DRESS or 279 
infection. Secondly, in cases of polymedication it is not easy to accurately determine 280 
and remove the culprit drug causing DRESS. 281 
 282 
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CRP, PCT leucocyte and eosinophil values 283 
In the present study, the mean CRP value was 109.2 ± 79.4 in 93 cases. No CRP 284 
values were within the normal laboratory range (<10 mg/L). The diagnostic 285 
performance of a CRP cut-off value of 99.4 mg/L in distinguishing between patients 286 
with DRESS alone and patients with an additional cause of inflammation was 287 
moderate (ROC-AUC 0.717) [72]. A study of 24 DRESS patients revealed a mean 288 
CRP value of 131 mg/L [5]. A further study of CRP and PCT profiles in 95 patients 289 
with a variety of different drug hypersensitivity reactions included 15 patients with 290 
DRESS syndrome [15]. Patients with DRESS showed a mean CRP value of 45.5 ± 291 
35.4 mg/L. The authors proposed a cutoff value of 66.7 mg/L in order to distinguish 292 
delayed-type drug reactions (95 measurements) from bacterial infection (47 293 
measurements) [15]. 294 
Mean PCT value was above 1 ng/mL in the present study. Values above 1 ng/mL are 295 
considered to indicate bacterial infection or sepsis [8-11]. A concurrent bacterial 296 
infection was not excluded in a quarter of the cases in our study. The PCT values of 297 
nine such cases showed a mean value of 1.68 ng/mL and a median value of 1.37 298 
ng/mL. This was in contrast to the median value of 0.67 ng/mL among patients who 299 
did not have another cause of inflammation. The mean value in this group was, 300 
however, higher than among patients with an additional cause of inflammation due to 301 
an outlying high value (30.17 ng/mL). The difference in PCT values was not 302 
significant between the two groups and the diagnostic performance (using a cut-off of 303 
2.74 ng/mL) was low (ROC AUC 0.677), possibly due to the small sample size. In the 304 
study by Yoon and colleagues mean PCT values were 0.79 ± 1.54 ng/mL for 15 305 
patients with DRESS syndrome and a cut off value of 1.67 ng/mL distinguished well 306 
between patients with  delayed-type drug reactions from bacterial infection (ROC 307 
AUC 0.95) [15]. Both the current study and the study by Yoon and colleagues 308 
observed PCT values which were clearly > 1 ng/mL in the absence of infection.  This 309 
may be due to the immune-mediated organ injury which is a hallmark of DRESS. 310 
Indeed PCT elevation has been observed in cases of liver injury independent of the 311 
presence of bacterial infection [73]. Rule and colleagues found median PCT values 312 
above 1.57 ng/ml among 59 patients with acute liver failure alone without sepsis. 313 
There was also no significant difference in PCT values between 56 patients with and 314 
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59 patients without bacterial infection. The authors suggested that severe hepatocyte 315 
necrosis causes inflammation resulting in elevated PCT levels.  316 
Mean leucocyte counts, a further marker of inflammation, were elevated above the 317 
normal laboratory range of 10 G/L and there was no significant difference in mean 318 
leucocyte counts between cases where an additional reason for inflammation beside 319 
DRESS could and could not be excluded. This suggests that the leucocyte count is 320 
not useful in distinguishing between these two types of patients with DRESS 321 
syndrome.  322 
Eosinophil counts had mean values over 1.5 G/L in both RPVC and literature cases. 323 
Mean eosinophil counts were significantly higher in cases where an additional 324 
inflammatory condition beside DRESS was not excluded. This was unexpected, as 325 
bacterial infection – which was the commonest reason for inflammation in addition to 326 
the DRESS syndrome– is not typically associated with eosinophilia.  We recommend 327 
interpreting this finding with caution, however, as the sample size is small and the 328 
case-mix heterogeneity is large. 329 
A limited number of paired PCT- and other laboratory marker measurements could 330 
be assessed for correlation (Table 5).  PCT correlated with liver function test 331 
measurements (most strongly with gamma glutamyl transpeptidase) indicating that 332 
PCT in DRESS may be an indicator of hepatic tissue damage as found by other 333 
investigators [73], There was no correlation between PCT and eosinophil count (21 334 
paired observations), suggesting that the pathomechanisms of PCT elevation and 335 
eosinophilia in DRESS syndrome are independent of each other.   336 
Limitations 337 
A retrospective study design is associated with more missing data than a prospective 338 
study and due to the nature of the data sources, investigation was limited to only a 339 
single measurement during the course of the condition.  There was a clear paucity of 340 
PCT measurements, possibly reflecting the general perceived use of this biomarker 341 
in clinical practice. However, cases of DRESS are rare and prospective studies take 342 
several years to complete.  The rarity of the condition also leads to small sample 343 
sizes. An additional limitation is the higher percentage of “definite” cases among the 344 
cases reported in the literature. This may reflect publication bias and the incomplete 345 
nature of the information available to the RPVCs, including the results of subsequent 346 
allergy tests. Further investigation is required to define the use of CRP and PCT 347 
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markers in achieving better management of DRESS cases with and without 348 
concurrent infection or other causes of inflammation. 349 
 350 
Conclusions 351 
CRP and PCT values were found to be elevated in this retrospective observational 352 
study of 94 possible, probable and certain DRESS syndrome cases, even among 353 
cases where concurrent infection was excluded.  CRP values were significantly 354 
higher among patients with possible additional causes for inflammation.  Additionally, 355 
a PCT value above the normal cut-off highly suggestive of bacterial infection may 356 
result from DRESS syndrome-associated inflammation alone.  Evaluating CRP- and 357 
PCT-values in the light of these findings might help physicians to distinguish between 358 
cases of DRESS syndrome with and without concurrent infection or other causes of 359 
inflammation. This may further aid decision-making regarding the best treatment plan 360 
for individual cases.   361 
  362 
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Accompanying Statement 363 
Some of the data for this work were obtained from Swissmedic who report to the 364 
WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden. Data 365 
from spontaneous reporting are inhomogeneous as a result of different reporting 366 
policies and are vulnerable to underreporting and reporting bias. The information 367 
contained in this work comes from a variety of different sources and the likelihood of 368 
a causal relationship is not the same in all reports. The information does not 369 
represent a pharmacovigilance signal or the opinion of Swissmedic or the World 370 
Health Organization. 371 
The authors do not have any conflicts of interest to declare.   372 
 373 
Figure legends 374 
Figure 1 Inclusion of RPVC and literature cases. 375 
Figure 2 Distribution of measured CRP and PCT values of all cases. The first column 376 
indicates normal laboratory range of CRP <10mg/L and PCT <0.1ng/mL.  377 
Figure 3 Boxplots showing the median, interquartile range and range of CRP and 378 
PCT values of DRESS cases without (group A) and with a possible additional cause 379 
for inflammation (group B).  The dashed line indicates normal laboratory range of 380 
CRP <10mg/L and PCT <0.1ng/mL. To optimize graphical display, a single PCT 381 
outlier (30.17 ng/mL in group A) is not depicted, but its value was included in the 382 
calculations. 383 
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Table 1 Case characteristics of all cases together and RPVC and literature cases separately. 
    All cases RPVC cases Literature cases  p-value 
Total number of cases 94 39   55    
Age (mean ± SD, min-max)  53.2 ± 22.6 (6-93) 60 ± 18 (22-93) 48.1 ± 22.7 (6-88) 0.06 
Female, n (%) 
 
55 (59) 23 (59) 
 
32 (58) 
 
0.88 
RegiSCAR classification [1]              
Definitea, n (%)   38 (40) 9 (23) 
 
29 (53) 
 
0.005 
Probableb, n (%)  38 (40) 18 (46) 
 
20 (36) 
 
 
Possiblec, n (%)  18 (19) 12 (31) 
 
6 (11) 
 
 
Cases with no other cause for inflammation, n (%) 71 (76) 25 (64) 
 
46 (84) 
 
 
Cases with possible additional cause for 
inflammation, n (%) 23 (24) 14 (36)  
9 (16) 
 
0.04 
Total numbers of culprit drugs  124 63   61    
Causality `certain`d, n (%)  1 (1) 
 
not given 
 
 
Causality `probable`d, n (%)  17 (27) 
 
not given 
 
 
Causality `possible`d, n (%)  45 (71)  not given   
a RegiSCAR score > 6 
b RegiSCAR score 4 – 5 
c RegiSCAR score 2 – 3 
d [20] 
16 
 
Table 2 Implicated drugs 1 
 All cases 
Cases with >1 possible culprit drug (%) 17/94 (18) 
Indication for culprit drug   
Arthritis/colitis/vasculitis 16 
Gout prophylaxis 12 
Epilepsy, migraine, trigeminal neuralgy 24 
Antibacterial use, sepsis excluded 9 
Bacterial Infection, sepsis not excluded 20 
Other (fungal infection, HIV, tumor, 
thrombus propylaxis, ulcer prophylaxis, 
psychosis) 
13 
Total number of culprit drugs [number (%)] 124 (100) 
Antibacterial total [number (%)] 39 (31) 
Amoxicillin 2 
Azithromycin 1 
Benzylpenicillin 1 
Cefazolin 1 
Ceftriaxone 2 
Cefuroxime [22] 1 
Ciprofloxacin 2 
Clindamycin 1 
Daptomycin 1 
Ertapenem 1 
Ethambutol [23, 24] 2 
Imipenem 1 
Isonazid 1 
Levofloxacin 1 
Metronidazole 3 
Minocycline [25] 1 
Piperacillin/Tazobactam 1 
17 
 
Pyrazinamide 1 
Rifampicin [26] 4 
Teicoplanin 1 
Vancomycin [26-32] 10 
Sulfamides total [number (%)] 18 (14) 
Dapsone [33] 1 
Salazosulphapyridine [34] 1 
Sulfamethaxole/Trimetoprim [35] 3 
Sulfasalazine [36- 44, 69] 13 
Antiepileptic total [number (%)] 29 (23) 
Carbamazepine [13, 14, 45- 51, 58] 11 
Diphenylhydantoin [52] 1 
Lacosamide 1 
Lamotrigine [53, 54] 5 
Levetiracetam [12, 55] 4 
Phenobarbital [56] 1 
Phenytoin [57] 3 
Topiramate 1 
Valproate [58] 2 
Other total [number (%)] 38 (31) 
Antiviral Nevirapine 2 
 Lamivudine 1 
 Raltegravir [59] 1 
Antimycotic  Itraconazole 1 
 L-Amphotericin B 
[60] 
1 
Allopurinol [61-64] 14 
NSAID and related Ibuprofen 1 
 Paracetamol 1 
 Metamizole 1 
Neuroleptic Clozapine 1 
18 
 
 Haloperidol 2 
 Quetiapine 1 
Diuretic Furosemide 1 
Heparin Enoxaparin [65] 1 
 Dalteparin 1 
Small molecule inhibitor Sorafenib [66] 1 
Protonpump inhibitors Omeprazole [67] 1 
 Pantoprazole 2 
Levothyroxine 1 
Strontium Ranelate [68] 1 
Tamsulosin 1 
Tribulus terrestris 1 
19 
 
 1 
Table 3 Mean and median values of CRP, PCT, leucocyte and eosinophil counts  2 
 3 
 All cases 
 CRP measurements, n (%) 93 (99) 
 CRP mean ± SD [min- max] mg/L 109.2±79.4 [11.5-420] 
 CRP median [interquartile range] mg/L 90.0 [62-138] 
 PCT measurements, n (%) 25 (27) 
 PCT mean ± SD [min-max] ng/mL 2.44 ± 5.93 [0.05-30.17] 
 PCT median [interquartile range] ng/mL 0.69 [0.41-1.80] 
 Leucocyte count measurements, n (%) 77 (82) 
 Leucocyte count mean ± SD [min-max] G/L 14.49±11.82 [0.3-60] 
 Leucocyte count median [interquartile range] G/L 11.9 [6.77-16.37] 
 Eosinophil count measurements, n (%) 79 (84) 
 Eosinophil count mean ± SD [min-max] G/L 2.76 ±2.96 [0-13.96] 
 Eosinophil count median [interquartile range] G/L 1.89 [1.16-3.03] 
 4 
  5 
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Table 4 Differences in calculated mean and median values of CRP, PCT, leucocyte and eosinophil count in two groups of patients, group A 6 
without and group B with a possible additional cause for inflammation. 7 
 8 
 
A: DRESS only cause of 
inflammation  
B: Possible additional cause of 
inflammation p-value 
CRP measurements, n (%) 71 (100) 22 (96) 
 CRP mean ± SD [min- max] mg/L 92.9 ± 62.2 [11.5-346] 162.1 ± 104.2 [24.3-420] 0.003 
CRP median [interquartile range] mg/L 85.8 [56.8-106.5] 150.5 [104.8-195.5] 
 PCT measurements, n (%) 16 (23) 9 (39) 
 PCT mean ± SD [min-max] ng/mL 2.87 ± 7.38 [0.05-30.17] 1.68 ± 1.64 [0.19-5.09] 0.2821 
PCT median [interquartile range] ng/mL 0.67 [0.34-1.34] 1.37 [0.42-2.72] 
 Leucocyte count measurements, n (%) 61 (86) 16 (70) 
 Leucocyte count mean ± SD [min-max] G/L 14.52 ± 12.46 [0.3-60] 14.38 ± 9.32 [3.15-38.8] 0.2331 
Leucocyte count median [interquartile range] G/L 12.2 [6.77-15.7] 11.3 [8.49-17.76] 
 Eosinophil count measurements, n (%) 61 (86) 18 (78) 
 Eosinophil count mean ± SD [min-max] G/L 2.57 ± 3.02 [0-13.96] 3.36 ± 2.79 [0.51-10.4] 0.0421 
Eosinophil count median [interquartile range] G/L 1.89 [0.95-2.93] 2.23 [1.45-6] 
  9 
1 T-test performed on log-transformed data 10 
 11 
21 
 
 12 
Table 5 Correlation coefficients of PCT and other laboratory markers in patients with DRESS 13 
syndrome 14 
Laboratory parameter Number of paired 
measurements 
Correlation coefficient 
Alanine aminotransferase  15 0.69 
Aspartate aminotransferase  14 0.66 
Alkaline phosphatase  10 0.17 
Gamma glutamyl transpeptidase  7 0.93 
Bilirubin  4 0.13 
Creatinine 13 0.10 
Absolute Eosinophil count 21 0.12 
 15 
 16 
 17 
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